In 1958, the National Cancer Institute (NCI) initiated a program to screen more than 35,000 plant extracts for more than 20 years. One of the rarest medicinal plants among the 56 endangered species plants left after the 4th glaciers, it has a history of 2.5 million years on earth and is known as the "living fossil" of the plant kingdom. There are 11 species in the world. , there are 4 species and 1 variant in my country) to extract paclitaxel (only about 0.3g of paclitaxel powder can be extracted per 3kg of bark)
Paclitaxel is a natural anti-cancer drug isolated from the bark of the Pacific yew tree (Taxus brevifolia). Its discovery dates back to 1962, when botanist Arthur S. Barclay collected Pacific yew bark samples in Washington state and sent them to the Wisconsin Alumni Research Foundation for study. In 1964, Monroe E. Wall and Mansukh Wani isolated the active ingredient in a laboratory in Research Triangle Park, North Carolina, and named it Taxol in 1967. The unique anticancer mechanism of paclitaxel is to prevent the mitosis of cancer cells by stabilizing microtubulin, thus inhibiting tumor growth. Due to the limited resources of paclitaxel in the natural environment, scientists are also investigating the production of paclitaxel through methods such as semi-synthesis and microbial fermentation in order to achieve sustainable supply.
In 1964, cytotoxicity experiments demonstrated the biological activity of paclitaxel;
In 1969, paclitaxel was identified as the active ingredient, and in the same year, Wani et al. determined the chemical structure of the substance;
In 1978, the formulation of paclitaxel powder was determined;
In 1979, Horwitz et al. reported the mechanism of action of paclitaxel;
In 1980, he carried out the study of drug administration procedures, conducted toxicological experiments on paclitaxel, and completed the toxicological study in 1982;
From 1983 to 1987, the phase I clinical trial of paclitaxel was completed;
From 1987 to 1989, the phase II clinical trial of paclitaxel was completed;
After 1990, it was transferred to the phase III clinical trial of paclitaxel;
